Par Pharmaceutical Companies, Inc. (PRX: Quote) on Friday said it began shipping all strengths of modafinil tablets, a generic version of Teva's Provigil brand. Par's initial shipments will comprise generically-labeled presentations of the Provigil product.
Par acquired the U.S. marketing rights to modafinil from Teva when Teva acquired Cephalon in 2011. According to IMS Health data, annual sales in the U.S. for Provigil are around $1.1 billion.
Modafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder.
Modafinil is contraindicated in patients with a known hypersensitivity to modafinil, armodafinil or its inactive ingredients.
Click here to receive FREE breaking news email alerts for Par Pharmaceutical Companies Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com